BIOLINERX
Careers | Contact Us
search

Press Releases
March 23, 2017
Agalimmune’s lead asset, AGI-134, provides a unique approach for eliciting patient-specific, anti-tumor immune responses in multiple cancer types
March 20, 2017
Results to date confirm that single injection of BL-8040 mobilizes sufficient amounts of cells required for allogeneic transplantation without need for G-CSF

Top-line results expected by end of 2017
March 16, 2017
Management to hold a conference call at 9:00 a.m. EDT
January 17, 2017
Study is part of strategic research collaboration between MSD and MD Anderson Cancer Center aimed to evaluate KEYTRUDA in selected GI tumors using various combinations

61-70  Out of  309 Previous
 1   2   3   4   5   6   7   8   9   10   11   12   13   14   15 
 16   17   18   19   20   21   22   23   24   25   26   27   28   29 
 30   31 
Next